Secondary Logo

Journal Logo

Use of Lactobacillus casei Subspecies Rhamnosus GG and Gastrointestinal Colonization by Candida Species in Preterm Neonates

Manzoni, Paolo

Journal of Pediatric Gastroenterology and Nutrition: December 2007 - Volume 45 - Issue - p S190–S194
doi: 10.1097/01.mpg.0000302971.06115.15
Original articles
Free

Candida species increasingly cause morbidity and mortality in the premature infant in neonatal intensive care units, and the gut reservoir is the site from which dissemination most frequently starts in such patients. Specific antifungal prophylaxis is the most suitable strategy with which to limit the severity and the frequent neurodevelopmental impairment in survivors that is associated with neonatal invasive fungal infections. Recent interest has focused on the use of probiotics for the treatment of several diseases in neonatal patients. Pilot studies have implicated these organisms in necrotizing enterocolitis, sepsis, and urinary tract infections. Other applications of probiotic therapy in preterm neonates may also include the prevention of fungal colonization and of Candida-related disorders. Probiotics could provide an innovative and less invasive approach because they modify the bowel flora by colonizing the gastrointestinal tract. Basic research has shown that in mice models, the Lactobacillus casei subsp Rhamnosus GG (LGG) is effective in preventing Candida gut colonization and systemic dissemination. A pilot, randomized, double-blind, placebo-controlled trial in human preterm neonates has demonstrated that LGG administered in the first month of life significantly reduces enteric Candida colonization. The present article summarizes the state of the art about probiotics and Candida-related diseases in the preterm neonate and emphasizes the need for further investigations to determine unequivocally the possible role of LGG in the prevention and management of the fungal diseases in preterm neonates.

Departments of Neonatology and Neonatal Intensive Care Unit, S. Anna Hospital, Turin, Italy

Address correspondence and reprint requests to Paolo Manzoni, MD, Neonatology and NICU, S. Anna Hospital, Azienda Ospedaliera Regina Margherita–S. Anna, C. Spezia 60, 10136 Torino, Italy (e-mail: paolomanzoni@hotmail.com).

Back to Top | Article Outline

CANDIDA-RELATED MORBIDITY IN PRETERM NEONATES

Fungi (particularly Candida species) have become important causative agents of infections in preterm neonates. The various Candida species are now the third most frequent cause of late-onset sepsis in very low birth weight (VLBW) preterm neonates (birth weight <1500 g) in neonatal intensive care units (NICU) (1–3). The estimated incidence of systemic fungal infection (SFI) is between 1.6% and 9% and reaches 15% in extremely low birth weight (ELBW) neonates (birth weight <1000 g). Neonatal systemic (or invasive) fungal infections are associated with high severity, substantial morbidity, and neurodevelopmental impairment. Candida species–attributable mortality ranges from 25% to 55%, and according to recent reports, SFIs produce as many as 73% of deaths or neurodevelopmental impairments at 18 months of life (4).

Back to Top | Article Outline

CANDIDA COLONIZATION AND GUT RESERVOIR IN PRETERM NEONATES

Colonization by Candida species, detected from all of the sites that can be monitored with serial cultures, is the condition most frequently associated with the development of SFI (5,6). A thorough search will nearly always disclose previous colonization. Approximately 60% of VLBW neonates are thought to be colonized during their first month in an NICU, with 85% of them acquiring colonization horizontally (7). Many of the colonized neonates are eventually infected. Baley et al (8) calculated that among 100 VLBW neonates, 33% were colonized and 7 of them experienced progression to SFI.

Examination of the digestive tract (cultures from pharyngeal swabs, gastric aspirate, feces, and rectal swabs) shows it to be the colonization site with the greatest predictivity for subsequent dissemination. Its colonization at various levels is a well-known risk factor for dissemination and SFI in preterm neonates, and rectal swab positivity is seen as an expression of colonization tout-court(9).

Preterm neonates in intensive care are, in any event, at high risk of intestinal disorders with proliferation of a pathogenic microflora (including fungi). In the preterm infant, the methods used in neonatal intensive care, such as treatment with antibiotics, total parenteral nutrition, or nursing in incubators, may delay or impair the intestinal colonization process. Preterm neonates are thus slower to acquire commensals such as bifidobacteria and are more susceptible to pathogenic colonization (10). In addition, their oral feeding cannot always be started and maintained. It is also known that the intestine of the premature infant has poor motility and is predisposed to bacterial overgrowth (11). The digestive tract is thus regarded as the most important reservoir and site for colonization by all kinds of pathogens and subsequent sepsis, including fungal.

Back to Top | Article Outline

CURRENT PROPHYLACTIC STRATEGIES

Research has focused on devising an optimum prophylactic strategy to reduce fungal colonization rates and thereby reduce the incidence of SFI (12). Antifungal systemic drugs, mostly fluconazole, have been tested with promising results (9,13–20). In all studies of fluconazole, it was consistently found to decrease the incidence rates of Candida species colonization in preterm neonates in NICU. However, it must be admitted that what should be done and how, and for which groups of preterm neonates, is far from clear. Some by no means secondary questions, in fact, are still open, and further prospective clinical investigations are needed. Some workers believe that the onset of adverse reactions to fluconazole and the selection of drug-resistant strains are subjects that remain to be clarified. The cost:benefit ratio of fluconazole prophylaxis and the type of population at risk for which it could best be used are other doubtful issues, along with the best outcome parameters for assessment of its effectiveness: colonization, incidence of SFI, the colonization-to-infection switch rate, mortality, length of hospital stay, and sequelae. For all of these reasons, the use of antifungal agents still raises questions and has not yet been established as the standard of care (21–24). Probiotics could provide an innovative and less invasive approach because they modify the bowel flora by colonizing the gastrointestinal tract.

Back to Top | Article Outline

MIGHT PROBIOTICS WORK?

The background for the efficacy of probiotics in preterm neonates comes from the observation that premature infants have fewer episodes of late-onset sepsis, necrotizing enterocolitis, diarrhea, and urinary tract infection, and they need less antibiotic therapy when fed their own mothers' milk in comparison with similar infants who are fed formula (25–27). Breast-feeding, in fact, allows close contact between the mother and her infant, and mammary milk has biofactors that help establish bifidobacteria and lactobacilli (the so-called “bifidus flora”) as predominant intestinal bacteria (28). Not only maternal milk nutrients but also probiotic bacteria and/or prebiotics (nutritional substrates that promote the growth of probiotic bacteria) through their stimulation of a normal commensal microflora may also play an important role in the regulation of interleukin-8 and neutrophil infiltration into the intestine development, in enhancement of the barrier function, and in the composition of the neonatal gut microbiota (29–36).

The birth of an extremely preterm infant interrupts early nutrition with maternal milk that occurs when the neonate is healthy and at term. Preterm infants cannot have close maternal contact, cannot leave the hospital shortly after birth, are often subject to delayed breast-feeding, and thus acquire intestinal flora from the NICU. In some studies, probiotics have been demonstrated to be effective in reducing the overgrowth of pathogens in the preterm neonate's gut and reducing the incidence of necrotizing enterocolitis and bacterial sepsis (37–47). In the light of these findings, may we hypothesize any relationships between probiotics and Candida species in the preterm neonate in the NICU?

In humans, Candida species is a commensal microorganism, and the enteric reservoir is a major site of fungal colonization inasmuch as Candida species adhere to gut. As mentioned above, colonization by Candida species is the most important predictor of invasive fungal disease, and the gastrointestinal tract is the site of colonization that is most frequently implicated in subsequent systemic dissemination. It is thus obvious that strategies affecting the fungal enteric reservoir may presumably lead to the avoidance of many potential systemic disseminations of fungi from the gut.

Studies in mice have shown that probiotics may interfere with fungi in the enteric reservoir. Lactobacillus casei subsp Rhamnosus GG (LGG) reduces both enteric colonization and SFI (48,49). Various mechanisms could be responsible for this protection. In the aforementioned studies, LGG was found to act at several levels simultaneously to reduce both Candida species colonization and systemic infection: exclusion of fungi by competition, prevention of adhesion, reduction of their ability to colonize the mucosa through an enhanced IgA response, changes in mucosal permeability enhancing the barrier effect, and immunomodulation with modification of the immune response to their products.

Also, in humans, it is feasible that colonization by benign flora such as LGG can afford protection against the proliferation of fungi in the gastrointestinal tract. An in vivo model of these interactions is the use of probiotics to prevent recurrences of vulvovaginal candidiasis (49–53). In vitro studies have shown that lactobacilli can inhibit the growth of Candida albicans and/or its adherence on the vaginal epithelium. The results of some clinical trials support the effectiveness of lactobacilli, among them Lactobacillus rhamnosus GG, administered either orally or intravaginally, in colonizing the vagina and/or preventing the colonization and infection of the vagina by C albicans. Because of this promising evidence, some practitioners use probiotics empirically for the prevention of such diseases.

Back to Top | Article Outline

A PILOT STUDY

The first evidence of a positive effect of probiotics in the prevention of fungal enteric colonization in human neonates comes from a prospective, randomized, double-blind clinical trial performed in 2006 in Italy (54). In this study, 80 preterm VLBW infants were randomly assigned during the first 3 days of life to receive either LGG at a dosage of 6 × 109 colony-forming units with human milk (LGG group, n = 39) or human milk alone (control group, n = 41) for 6 weeks or until discharge if earlier than 6 weeks. The neonates were all older than 3 days and had started oral feeding with human milk (either from their own mothers or from donors) before randomization. None had baseline fungal colonization at enrollment, and they were not undergoing any other form of antifungal prophylaxis. Enteric fungal colonization was monitored by surveillance (oropharyngeal, stool, gastric aspirate, and rectal cultures) performed weekly.

The primary efficacy endpoint was the overall incidence of enteric fungal colonization, expressed as incidence of colonization (at least 1 positive result from the cultures) during the first 6 weeks of stay in the NICU. The secondary outcomes were the intensity of fungal colonization; the ratio of non-albicans to albicans Candida species in the 2 groups; the incidence of bacterial sepsis (caused by both gram-positive and gram-negative microorganisms); the incidence of sepsis by LGG; necrotizing enterocolitis, both surgical and stage III; and the incidence of SFI. The results showed that the total number of positive cultures, the mean number of fungal isolates obtained from each patient, and the mean number of fungal isolates obtained from each colonized patient were significantly lower in the LGG group (P = 0.009, P = 0.005, and P = 0.005, respectively). The overall gastrointestinal colonization rate was 23.1% in the infants receiving LGG and 48.8% in those with placebo (P = 0.01). Clustering the analysis for weight range, the reduction of overall gastrointestinal colonization was significant in neonates with birth weight 1001 to 1500 g (from 42.9% to 14.8%; P = 0.02) but not in neonates with birth weight below 1000 g (P = 0.27).

The distribution of fungal species, in particular the ratio of C albicans to C non-albicans, was similar, with C albicans representing 78% of the isolates in the LGG group and 70% in the placebo group (P = 0.32). In no case was LGG isolated from blood cultures or other specimens. Similarly, LGG was never the suspected causal agent of sepsis that was not microbiologically documented in any neonate studied. No adverse effects occurred. The incidence of SFI before discharge was slightly, but not significantly, lower in the LGG group (10.3% vs 12.2%; P = 0.53), as was the incidence of surgical necrotizing enterocolitis (0% vs 2.5%; P = 0.51).

The 2-fold reduction in gut colonization by fungi in the VLBW neonates given LGG in this study is in line with most of the studies performed in preterm infants given a prophylactic antifungal drug, thus allowing the authors to consider LGG supplementation as a promising minimally invasive prophylactic strategy in such settings. The authors remark that these results were obtained with no adverse effect, particularly with no onset of sepsis caused by LGG. Moreover, the results did not seem to be attributable to the type of feeding (human milk might positively influence the gut microflora), inasmuch as human milk was the main nutritional policy in both randomized groups. The relative frequencies of Candida subspecies were unmodified in the 2 groups, meaning that the beneficial effect of LGG was unspecific (ie, evenly distributed over all fungal colonies).

In this study, the infants weighing 1001 to 1500 g benefited more from the use of probiotics than did those weighing less than 1000 g: the paradox that a greater per-kilogram dosage had a lesser effect was possibly due to the even greater increase in the overall risk for colonization with the decrease in birth weight. We suggest that combinations of drugs and probiotics may be beneficial in all VLBW neonates, with greater reliance on probiotics in the bigger neonates and vice versa in the smaller ones. Such combinations should allow a reduction in the dosage of drugs needed to suppress colonization. Clearly, the optimal combination in each case should not be a strict reflection of the current separation between infants with birth weight below 1000 g and those weighing between 1001 and 1500 g, and may be adjusted as required; for example, more reliance could be placed on antifungal drugs in NICUs with higher frequencies of colonization and invasive fungal disease.

Back to Top | Article Outline

THE FUTURE

It now remains to be determined, in a sufficiently large population, whether the decrease in gastrointestinal fungal colonization produced by LGG also results in a corresponding reduction of SFI, as may logically be expected. The pilot study by Manzoni et al (54) was designed and powered to test the effect of LGG on colonization, not on SFI. In this study, a slight decrease in the SFI rates occurred in the LGG group, but it was not significant. LGG dosages higher than those used in that study may enhance the direct positive effect of the probiotic on immunity in the infants who receive lesser benefit. However, it is noteworthy that the per-kilogram dosages used were considerably higher than those recommended by the producing company, and the possibility that the probiotic will be carried indefinitely should raise a safety concern.

In conclusion, although the results on colonization are encouraging, the hypothesis that LGG or other probiotics may be effective in preventing SFI must be tested in ad hoc studies. These studies must be not only adequately powered (a few hundred randomized VLBW neonates are needed) but also dose finding, to better address the question whether the impact of LGG on invasive disease may depend on changes in the administered dose.

Lactoferrin (LF) is a protein of the wide array of biologically active components of human milk. It acts in vivo together with many other probiotics and prebiotics or symbiotic nutrients, inhibiting the growth of pathogenic bacteria and viruses in the enteric tract. Recent data from basic research suggest that the combination of LGG and LF could boost the defenses of an immature intestine. Sherman et al (55), in fact, has shown that LGG plus LF administered orally limited the intestinal growth of Escherichia coli in newborn rats more effectively than did LGG alone, and without increasing the number of LGG colonies. Administration of LF has thus been proposed as a way of reducing the incidence of necrotizing enterocolitis and sepsis originating in the intestine (56). Moreover, Tanida et al (57) recently demonstrated a synergic antifungal effect of several peptides, including LF, used in combination with antifungal drugs.

On the basis of these background data, the Neonatal Fungal Infections Task Force of the Collaborative Neonatal Infections Study Group (affiliated with the Italian Society of Neonatology) has designed a blind, multicenter, international, randomized study to test the effectiveness of an antifungal prophylaxis with LGG plus LF (Dicoflor 60 + LF100; Dicofarm, Rome, Italy) in VLBW neonates in the NICU. Thanks to the large number of centers involved in recruiting (15 to 20 NICUs in Italy and the United States, with an estimated 500 to 800 VLBW infants enrolled), the primary endpoint of this study will be not only the incidence of intestinal fungal colonization but also the incidence of SFI, of bacterial sepsis, and of necrotizing enterocolitis. Neonates will be randomized in 3 groups (LGG + LF, LF alone, placebo), and oral administration of the nutrients in the study will last 6 weeks, regardless of the type of milk used. It is hoped that the results of this study will shed a clearer light on the effectiveness of the strategy based on probiotic oral supplementation in the prevention of fungal-related morbidity in preterm infants.

Back to Top | Article Outline

REFERENCES

1. Makhoul IR, Sujov P, Smolkin T, et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002; 109:34–39.
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285–291.
3. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr 2005; 147:135–141.
4. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117:84–92.
5. El-Masry FAY, Neal TJ, Subhedar NV. Risk factors for invasive fungal infection in neonates. Acta Paediatr 2002; 91:198–202.
6. Bendel CM. Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis. Semin Perinatol 2003; 27:357–364.
7. Saiman L, Ludington E, Dawson JD, et al. National Epidemiology of Mycoses Study Group. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119–1124.
8. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78:225–232.
9. Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107:293–298.
10. Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr 2001; 73:1147S–1151S.
11. Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100:2560–2568.
12. Huang YC, Li CC, Lin TY. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J 1998; 17:819–822.
13. Sims ME, Yoo Y, You H, et al. Prophylactic oral nystatin and fungal infections in very-low-birth-weight infants. Am J Perinatol 1988; 5:33–36.
14. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660–1666.
15. Manzoni P, Arisio R, Mostert M, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year retrospective cohort study. Pediatrics 2006; 117:e22–e32.
16. Bertini G, Perugi S, Dani C, Filippi L, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005; 147:162–165.
17. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005; 147:172–179.
18. Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005; 147:166–171.
19. Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006; 117:1243–1252.
20. Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006; 26:550–555.
21. Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics 2001; 107:404–405.
22. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Syst Database Rev 2002; 3.
23. Austin NC, Darlow B. Prophylactic oral anti-fungal agents to prevent systemic Candida infection in preterm infants (protocol for a Cochrane review). Cochrane Syst Database Rev 2002; 3.
24. Fanaroff AA. Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics 2006; 117:214–215.
25. Hylander MA, Strobino DM, Dhanireddy R. Human milk feedings and infection among very low birth weight infants. Pediatrics 1998; 102:E38.
26. Kashyap S, Ohira-Kist K, Abildskov K, et al. Effects of quality of energy intake on growth and metabolic response of enterally fed low-birth-weight infants. Pediatr Res 2001; 50:390–397.
27. Lucas A, Morley R, Cole TJ, et al. Breast milk and subsequent intelligence quotient in children born preterm. Lancet 1992; 339:261–264.
28. Harmsen HJM, Wildeboer-Veloo ACM, Raangs GC, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000; 30:61–67.
29. Zhang L, Li N, des Robert C, et al. Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model. J Pediatr Gastroenterol Nutr 2006; 42:545–552.
30. Liboni K, Li N, Neu J. Mechanism of glutamine-mediated amelioration of lipopolysaccharide-induced IL-8 production in Caco-2 cells. Cytokine 2004; 21:57–65.
31. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004; 72:5308–5314.
32. Bai AP, Ouyang Q, Zhang W, et al. Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells. World J Gastroenterol 2004; 1:455–457.
33. Yasui H, Nagaoka N, Mike A, et al. Detection of bifidobacterium strains that induce large quantities of IgA. Microb Ecol Health Dis 1992; 5:155–162.
34. Kennedy RJ, Kirk SJ, Gardiner KR. Mucosal barrier function and the commensal flora. Gut 2002; 50:441–442.
35. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276:G941–G950.
36. Brand S, Reinecker HC. An enhanced barrier is a better defense: effects of probiotics on intestinal barrier function. Inflamm Bowel Dis 2002; 8:67–69.
37. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69:1052S–1057S.
38. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteric administration of Lactobacillus acidophillus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999; 3:197–202.
39. Caplan MS, Miller-Catchpole R, Kaup S, et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology 1999; 117:577–583.
40. Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: possible role of probiotic supplementation. J Pediatr Gastroenterol Nutr 2000; 30 Suppl 2:S18–S22.
41. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147:192–196.
42. Neu J, Caicedo R. Probiotics: protecting the intestinal ecosystem? J Pediatr 2005; 147:143–146.
43. Claud EC, Walker WA. Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J 2001; 15:1398–1403.
44. Millar M, Wilks M, Costeloe K. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal Ed 2003; 88:F354–F358.
45. Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants: a prospective double-blind study. Biol Neonate 2002; 82:103–108.
46. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115:1–4.
47. Kliegman RM, Willoughby RE. Prevention of necrotizing enterocolitis with probiotics. Pediatrics 2005; 115:171–172.
48. Wagner RD, Pierson C, Warner T, et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 1997; 65:4165–4172.
49. Wagner RD, Pierson C, Warner T, et al. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J Food Prot 2000; 63:638–644.
50. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006; 58:266–272.
51. Hamad M, Muta'eb E, Abu-Shaqra Q, et al. Utility of the oestrogen-dependent vaginal candidosis murine model in evaluating the efficacy of various therapies against vaginal Candida albicans infection. Mycoses 2006; 49:104–108.
52. Sobel JD. Does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Curr Infect Dis Rep 2005; 7:443–444.
53. Strus M, Kucharska A, Kukla G, et al. The in vitro activity of vaginal Lactobacillus with probiotic properties against Candida. Infect Dis Obstet Gynecol 2005; 13:69–75.
54. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42:1735–1742.
55. Sherman MP, Bennett SH, Hwang FF, et al. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals 2004; 17:285–289.
56. Sherman MP, Petrak K. Lactoferrin-enhanced anoikis: a defense against neonatal necrotizing enterocolitis. Med Hypotheses 2005; 65:478–482.
57. Tanida T, Okamoto T, Ueta E, et al. Antimicrobial peptides enhance the candidacidal activity of antifungal drugs by promoting the efflux of ATP from Candida cells. J Antimicrob Chemother 2006; 57:94–103.
Keywords:

Candida species; Lactobacillus rhamnosus GG; Neonate; Preterm; Probiotic

© 2007 Lippincott Williams & Wilkins, Inc.